Emerging antiamyloid agents and their putative mechanisms of action. The mechanisms of action of the antiamyloid mAb therapies currently in clinical trials are based on enhancing phagocytic clearance of amyloid deposits. Whether the removal of the deposits will enable durable organ recovery and prolong survival or time to organ failure is unknown. Doxycycline and EGCG are antiamyloid agents whose detailed mechanisms of action are not as well understood, given the limited amount of data from experimental models. The key points remain that antiamyloid therapies must be shown to provide measurable benefit to patients and are likely to be more effective when the production of the amyloid-forming protein is stopped.